| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Lacosamide |
| Brand | Vimpat® |
| Indication | As monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. The Applicant is seeking reimbursement for an extension to the product license to cover children (≥4 years of age) and adolescents (≤ 15 years of age). |
| Assessment Process | |
| Rapid review commissioned | 11/09/2017 |
| Rapid review completed | 31/10/2017 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended at the submitted price |
